The global antifungal drugs market was valued at USD 10.7 billion in 2015 and is expected to reach a value of USD 12.6 billion by 2025. The increasing incidence of fungal infections worldwide is the key contributing factor for the growth of the antifungal drugs market in the coming years. Rising adoption of immunosuppressive andantineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics have resulted in the increasing incidence of fungal infections in the recent years.
The growing geriatric population prone to infectious diseases and higher prevalence of chronic conditions, including HIV and cancer, are further contributing toward the rising demand for antifungals to treat opportunistic fungal infections over the forecast period. The large demand for these fungistatic agents is due to the nature of fungal infections, which are difficult to diagnose, yielding high mortality and morbidity rates.
View summary of this report @ http://www.grandviewresearch.com/industry-analysis/antifungal-drugs-market
Further Key Findings from the Study Suggest:
·
Echinocandins segment is anticipated to exhibit
lucrative growth owing to their cell wall-specific fungicidal property coupled
with their broad-spectrum activity against Aspergillus and Candida
species without cross-resistance risks
·
Candidiasis indication segment is anticipated to
witness the fastest CAGR over the forecast period due to the increasing drug
resistance of the Candida speciesto Azoles
·
North America held the largest market share as
of 2015, which is attributable to higher awareness levels pertaining to the
treatment of fungal infection and presence of target diseases in the population
·
Asia pacific is predicted to exhibit the fastest
growth due to improving healthcare facilities coupled with rising government
initiatives to create awareness of infectious diseases amongst the population
·
The companies are focusing on the development of
effective therapeutic agents for the treatment of systemic fungal infections in
immune-compromised patients
·
Numerous ongoing public-private partnership
agreements in the pharmaceutical industry for the development of novel
therapeutics is predicted to provide this market with lucrative growth
opportunities
·
For example, the public-private partnership,
namely Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator is
anticipated to provide USD 44 million in 2016 and around USD 350 million in the
coming 5 years to boost the R&D pipeline
·
The partners involved in this partnership are
the U.S. Department of Health and Human Services, the Antimicrobial Resistance
Centrein England, and Boston University School of Law
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the antifungal drugs market by drug class, indication, and region:
Global Antifungal Drugs Class Outlook (Revenue, USD Million, 2014 - 2025)
·
Azoles
·
Echinocandins
·
Polyenes
·
Allylamines
·
Others
Global Antifungal Drugs Indication Outlook (Revenue, USD Million,
2014 - 2025)
·
Dermatophytosis
·
Aspergillosis
·
Candidiasis
·
Others
Antifungal Drugs Regional Outlook (Revenue, USD Million, 2014 -
2025)
·
North America
o
U.S
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
Japan
o
China
o
India
·
Latin America
o
Brazil
o
Mexico
·
The Middle East and Africa
o
South Africa
For press release of this report - http://www.grandviewresearch.com/press-release/global-antifungal-drugs-market
No comments:
Post a Comment